And the presence of the Barcelona Science Park, which is the first science park in Spain that is home to three research institutes and more than 70 companies, make the city a viable location for ...

Scientists have made a breakthrough that could lead to effective treatments for lymphedema, a painful swelling condition for which there is currently no cure. Lymphedema can be congenital or caused by ...

Many of us believe that full-fat milk, butter, and cheese are not advised for heart patients, as they may raise the risk of clogged arteries and cause heart attacks. Nighttime Nutrition: 7 Surprising ...

Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, today's ...

A new discovery involving the larva of zebrafish shows promise for treating or preventing painful lymphoedema.

Learn more about whether IDEAYA Biosciences, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

A new white paper issued by the Clayman Thyroid Center in Tampa, Florida, concludes that popular GLP-1 receptor agonists prescribed for weight control demonstrate that the agents show no cause, or ...

Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. The six assets don’t appear in Novartis’ Feb. 4 earnings presentation (PDF). A ...

Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One company is taking them to the Super Bowl so that anyone can try them. Hims ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

In this retrospective analysis, researchers studied adult patients who were diagnosed with non-metastatic breast cancer and received GLP1-RAs for at least 3 months.